AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.

Abstract

Recombinant human relaxin-2 (serelaxin), which has organ-protective actions mediated <i>via</i> its cognate G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), has emerged as a potential agent to treat fibrosis. Studies have shown that serelaxin requires the angiotensin II (AngII) type 2 receptor (AT₂R) to ameliorate renal fibrogenesis <i>in vitro</i> and <i>in vivo</i>. Whether its antifibrotic actions are affected by modulation of the AngII type 1 receptor (AT₁R), which is expressed on myofibroblasts along with RXFP1 and AT₂R, is unknown. We examined the signal transduction mechanisms of serelaxin when applied to primary rat renal and human cardiac myofibroblasts <i>in vitro</i>, and in three models of renal- or cardiomyopathy-induced fibrosis <i>in vivo</i>. The AT₁R blockers irbesartan and candesartan abrogated antifibrotic signal transduction of serelaxin <i>via</i> RXFP1 <i>in vitro</i> and <i>in vivo</i>. Candesartan also ameliorated serelaxin's antifibrotic actions in the left ventricle of mice with cardiomyopathy, indicating that candesartan's inhibitory effects were not confined to the kidney. We also demonstrated in a transfected cell system that serelaxin did not directly bind to AT₁Rs but that constitutive AT₁R-RXFP1 interactions could form. To potentially explain these findings, we also demonstrated that renal and cardiac myofibroblasts expressed all three receptors and that antagonists acting at each receptor directly or allosterically blocked the antifibrotic effects of either serelaxin or an AT₂R agonist (compound 21). These findings have significant implications for the concomitant use of RXFP1 or AT₂R agonists with AT₁R blockers, and suggest that functional interactions between the three receptors on myofibroblasts may represent new targets for controlling fibrosis progression.